PITTSBURGH, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026, in Boston. Company executives will take part in a fireside chat scheduled at 3:10 pm ET and host investor meetings throughout the day. A webcast of the presentation will be available here beginning at 3:10 pm ET on Tuesday, March 3, 2026 and will be posted on the Investors section of the Compa ...

Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.Redmile Group reported a purchase of 16,317 shares of Krystal Biotech (KRYS 0.33%) in its February 17, 2026, SEC filing, with the estimated transaction value at $3.43 million based on quarterly average pricing.What happenedAccording to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Redmile Group increased its position in Krystal Biotech by 16 ...

Krystal Biotech, Inc. (NASDAQ:KRYS) is among the 11 Best All-Time High Stocks to Buy According to Wall Street. On February 17, 2026, Jefferies analyst Roger Song raised the price target on Krystal Biotech, Inc. (NASDAQ:KRYS) to $371 from $310 and maintained a Buy rating. Roger Song noted another strong quarter and full year, with Vyjuvek and DEB U.S. revenue growth re-accelerating on robust demand and penetration reaching about 60%, while ex-U.S. expansion is expected to become a 2026 growth driver. Roger ...

Core Insights - Krystal Biotech (KRYS) reported Q4 2025 earnings per share (EPS) of $1.70, exceeding the Zacks Consensus Estimate of $1.62, and up from $1.52 in the same quarter last year [1][7] - Revenues for the quarter were $107.1 million, a 17.5% increase year over year, but fell short of the Zacks Consensus Estimate of $109 million, with all revenues coming from Vyjuvek sales [1][6] - The FDA approved Vyjuvek, the first revocable gene therapy, for treating dystrophic epidermolysis bullosa (DEB) in patients aged six months and older, and for at-home administration [2] Financial Performance - For Q4 2025, product revenues from Vyjuvek were $107.1 million, up from $91.1 million in the previous year, driven by strong patient uptake, with a gross margin of 94% [6][7] - For the full year 2025, total product revenues reached $389.1 million, a 34% increase year over year, with net earnings of $6.84 per share compared to $3.00 in 2024 [10] Market Access and Demand - The company secured over 660 reimbursement approvals for Vyjuvek in the U.S., facilitating nationwide access, while international demand remains strong with over 90 patients prescribed the therapy in Germany, France, and Japan [3][7] Research and Development - R&D expenses for Q4 were approximately $14.8 million, a 9.36% increase year over year, while SG&A expenses totaled about $41.4 million, up 32.5% due to increased headcount and marketing costs [8] - Krystal Biotech is advancing multiple candidates, including KB407 and KB707, with several data readouts and studies planned for 2026 [7][12] Pipeline Updates - KB407 is being evaluated for cystic fibrosis, with successful data from a multicenter study announced in January, and a registrational study planned for 2026 [13][14] - KB707 is in development for solid lung tumors, with the FDA granting RMAT designation for advanced non-small cell lung cancer [18] - The company is also developing KB304 for aesthetic applications, with a mid-stage study expected to start in 2027 [19]

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Core Viewpoint - The article emphasizes the importance of conducting thorough research and independent verification before making investment decisions, highlighting the inherent risks and volatility associated with stock investments [2][3]. Group 1 - The article provides informational content but does not serve as an exhaustive analysis of any featured company [2]. - It clarifies that the predictions and opinions presented are based on a probabilistic approach rather than absolute certainty [2]. - The author has no financial interest in the companies mentioned, ensuring an unbiased perspective [1]. Group 2 - The article stresses that past performance is not indicative of future results, cautioning readers against relying solely on historical data [3]. - It notes that the views expressed may not reflect those of the platform as a whole, indicating a diversity of opinions among contributors [3]. - The article highlights that the analysts involved may not be licensed or certified, which could affect the reliability of the information provided [3].

Financial Performance - Krystal Biotech reported earnings per share of $1.70, surpassing the estimated $1.62 [1][6] - The company achieved revenue of approximately $107.1 million, exceeding the estimated $105.1 million [1][6] - Revenue from VYJUVEK contributed to a total of $730.3 million since its U.S. launch [2][6] Liquidity and Financial Stability - The company ended the quarter with $955.9 million in cash and investments, indicating a strong liquidity position [3][6] - A current ratio of 10.14 suggests the company can easily cover its short-term liabilities [3] - The low debt-to-equity ratio of 0.0084 indicates minimal reliance on debt, providing financial stability [3] Valuation Metrics - The company's P/E ratio is 40.22, and the price-to-sales ratio is 21.47, reflecting investor confidence in its growth potential [4] - The enterprise value to sales ratio is 20.44, and the enterprise value to operating cash flow ratio is 43.30, highlighting a positive market outlook [4] - An earnings yield of 2.49% indicates a return on investment based on earnings [4] Strategic Focus and Future Goals - The company aims to support patients with dystrophic epidermolysis bullosa globally and plans to launch multiple products by 2030 [5] - Krystal Biotech intends to treat over 10,000 patients with rare diseases by 2030 [5] - Recent developments in cystic fibrosis research underscore the versatility of the company's approach [5]

Core Insights - Krystal Biotech reported strong revenue growth for Q4 2025 and full-year 2025, with net revenue from VYJUVEK reaching $107.1 million in Q4 and $389.1 million for the year, representing approximately 34% year-over-year growth [3][4][6] Financial Performance - R&D expenses for Q4 2025 were $14.8 million, up from $13.5 million a year earlier, while SG&A expenses increased to $41.4 million from $31.3 million, primarily due to higher headcount and costs associated with global launches [1] - Gross margin remained strong at 94% for both the quarter and the full year, with expectations to maintain margins in the 90% to 95% range for the foreseeable future [2] Market Expansion - The company is experiencing momentum in international markets, particularly in Europe and Japan, with over 90 DEB patients prescribed VYJUVEK across these regions [13] - U.S. commercial momentum is also strong, with more than 660 reimbursement approvals and over 500 unique prescribers since launch [6][9] Pipeline Developments - Krystal is advancing multiple programs, including KB407 for cystic fibrosis, with expected registrational readouts before year-end [5][18] - Protocol changes for KB801 and KB803 aim to facilitate at-home dosing, with data expected before year-end [19][20] Cash Position - The company ended 2025 with $955.9 million in cash and investments, providing a strong financial foundation for future growth [8]

Financial Data and Key Metrics Changes - The company reported net VYJUVEK revenue of $107.1 million in Q4 2025, marking a growth of almost 10% compared to the previous quarter and approximately 18% year-over-year [26][27] - Year-to-date VYJUVEK net revenue reached $389.1 million, an increase of approximately 34% compared to full year 2024 revenue [26] - Gross margin for Q4 was 94%, down from 96% in Q3 and 95% in Q4 of 2024, attributed to increased sales outside the U.S. which carry higher costs [27] Business Line Data and Key Metrics Changes - The U.S. commercial performance showed strong momentum with over 660 reimbursement approvals since launch and over 500 unique prescribers [10] - In Europe, the launch of VYJUVEK is progressing well, with over 90 DEB patients prescribed the treatment across Germany, France, and Japan [12][16] - The company aims to expand its distributor agreements to over 40 countries in 2026, having already signed agreements covering more than 20 countries [5] Market Data and Key Metrics Changes - The company is experiencing strong demand for VYJUVEK in various markets, with significant patient adoption in Germany and Japan [12][16] - Pricing negotiations are ongoing in Germany and France, with expectations to finalize agreements in the second half of 2026 for Germany and in 2027 for France [13][16] Company Strategy and Development Direction - The company is focused on expanding global access for VYJUVEK while advancing a pipeline of genetic therapies, with plans to initiate two additional registrational programs later in the year [6][34] - The strategy includes disciplined capital allocation and a commitment to self-launching new indications if approved [8][34] - The company is also exploring stock buyback options but prioritizes investments in its pipeline and potential M&A opportunities [52] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential from international markets, noting that there are more DEB patients outside the U.S. than within it [32] - The company anticipates that revenue may not track linearly with patient counts due to accruals and ongoing pricing negotiations [33] - Management highlighted the importance of registrational programs and the positive impact of recent FDA designations on development timelines [25][34] Other Important Information - The company ended the year with $955.9 million in combined cash and investments, positioning it well for future commercial launches and pipeline milestones [31] - The company received a Fast Track designation for KB111 and an RMAT designation for KB707, which can accelerate development timelines [25] Q&A Session Summary Question: Visibility into Q1 and contribution from ex-U.S. vs U.S. in 2026 - Management indicated that while ex-U.S. markets will be the predominant growth driver, U.S. demand is also accelerating, with expectations to break out revenue in Q1 [36][38] Question: Compliance rates in EU and Japan - Compliance in Europe is similar to the U.S. at launch, but Japan has a two-week prescription requirement that may affect long-term compliance [44][48] Question: Updates on pricing negotiations in Europe - Management expects to reach a pricing agreement in Germany in Q3 and anticipates that negotiations in France will extend into the first half of next year [55][56] Question: Changes in dosing regimens for ocular studies - The modified dosing regimens were designed to enhance patient compliance and convenience, with no changes to the dose volume or potency [75][76] Question: Patient distribution for VYJUVEK in Europe - Management noted that estimating patient numbers in Europe is challenging due to varying laws and logistics, but they are optimistic about the launch progress [63][64]

Financial Data and Key Metrics Changes - The company reported Q4 2025 net revenue of $107.1 million, marking a growth of almost 10% compared to the prior quarter and approximately 18% growth year-over-year [26][27] - Year-to-date net revenue for VYJUVEK reached $389.1 million, an increase of approximately 34% compared to full year 2024 revenue [26] - Gross margin for Q4 was 94%, down from 96% in Q3 and 95% in Q4 of 2024, attributed to increased sales outside the U.S. which carry higher costs [27] Business Line Data and Key Metrics Changes - VYJUVEK continues to show strong performance with total net revenue since launch exceeding $730 million [8] - The company added over 50 new prescribers in Q4 2025, reaching over 500 unique prescribers since launch in the U.S. [10] - In Europe, over 90 DEB patients have been prescribed VYJUVEK across Germany, France, and Japan, with ongoing momentum in Germany and France [12][13] Market Data and Key Metrics Changes - The company has signed distributor agreements covering more than 20 countries, aiming to expand to over 40 countries in 2026 [5] - Pricing negotiations in Germany and France are ongoing, with expectations for agreements in the second half of 2026 for Germany and 2027 for France [13][16] - The company has expanded its distributor network to include Israel, enhancing its market presence [16] Company Strategy and Development Direction - The company aims to build a durable commercial gene therapy business with disciplined capital allocation and a focus on expanding global access for VYJUVEK [7] - The strategy includes investing behind measurable execution milestones and advancing a focused pipeline, with plans to initiate two additional registrational programs later this year [6][8] - The company is committed to optimizing processes to support patients and providers, leveraging partnerships with advocacy organizations [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential from international markets, noting that there are more DEB patients outside the U.S. than within [31] - The company anticipates that revenue may not track linearly with patient counts due to accruals and ongoing pricing negotiations [32] - Management highlighted the importance of registrational programs and expressed optimism about upcoming clinical data readouts [33] Other Important Information - The company ended the year with $955.9 million in combined cash and investments, positioning it well for future commercial launches and pipeline milestones [30] - The company received Fast Track designation for KB111 and RMAT designation for KB707, which can accelerate development timelines [25] Q&A Session Summary Question: Visibility into Q1 and 2026 revenue contribution from U.S. vs. ex-U.S. - Management indicated that while ex-U.S. markets will be the predominant growth driver, demand in the U.S. is also accelerating, with expectations to break out revenue in Q1 [35][36] Question: Data supporting modified dosing regimens for ocular and NK - Management confirmed that the changes were made to enhance patient compliance and convenience, with confidence in the safety profile of the drugs [38][39] Question: Compliance rates in EU and Japan - Management noted that compliance in Europe has been similar to the U.S., but highlighted a potential burden in Japan due to the two-week prescription requirement [42][46] Question: Updates on pricing negotiations in Europe - Management expects to reach a pricing agreement in Germany in the second half of the year, while negotiations in France may extend into the first half of next year [53] Question: Impact of modified dosing regimens on study data - Management confirmed that the data generated to date will be included in the primary analysis, with no changes to the dose volume [73][75]